Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.05 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
News headline image
The Weight-Loss Craze Boosted The $186 Billion Telehealth Industry. What It Means For Investors. ↗
Telehealth companies are getting a fresh infusion of business thanks to obesity drugs. Find out which stocks are benefiting. 
Via Investor's Business Daily
News headline image
Why Shares in Novo Nordisk Soared This Week ↗
Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market. 
Via The Motley Fool
News headline image
Why Novo Nordisk Stock Popped Again Today ↗
A Wegovy pill may be the right medicine to get Novo Nordisk stock moving again. 
Via The Motley Fool
News headline image
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial ↗
Via Stocktwits
US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ ↗
Via Stocktwits
Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study ↗
Via Stocktwits
News headline image
Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today ↗
Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling stocks. 
Via The Motley Fool
Topics Government
News headline image
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs ↗
The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom. 
Via Benzinga
Topics ETFs
News headline image
Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal ↗
Novo Nordisk A/S (NYSE:NVO) is showing promising signs of recovery with weight-loss pills, heart-healthy benefits, and bullish analyst reports, following a similar path to UnitedHealth Group Inc's... 
Via Benzinga
Topics Artificial Intelligence
News headline image
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi &amp; Korsinsky to Learn More
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Novo Nordisk Pops 8% On 'Significant' Weight Loss For Oral Wegovy ↗
Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight. 
Via Investor's Business Daily
News headline image
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study ↗
Novo Nordisk's Wegovy cut cardiovascular risks more than tirzepatide in real-world data from patients with obesity and heart disease. 
Via Benzinga
News headline image
Why Is Everyone Talking About Novo Nordisk Stock? ↗
Competition in various directions is affecting the company's fastest-growing product. 
Via The Motley Fool
News headline image
'Offices Need To Start Feeling A Little Bit More Like Hotels,' Behind One CBRE Exec's Approach To The Future Of In-Person Work ↗
 
Via Benzinga
Dow Futures Surge After Fed Signals Possibility Of More Rate Cuts This Year: META, PLTR, PYPL, GOOGL Among Stocks To Watch ↗
Via Stocktwits
Topics Economy Stocks
News headline image
Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up ↗
The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity. 
Via Stocktwits
News headline image
Why Novo Nordisk Stock Popped Today ↗
Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now? 
Via The Motley Fool
News headline image
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
2 High-Yield Dividend Stocks You'll Wish You Had Bought 10 Years From Now ↗
These dividend payers cranked up their payouts over the past decade, and they could do it again. 
Via The Motley Fool
News headline image
Why Novo Nordisk Stock Popped Today ↗
The Wegovy maker reported positive results from a clinical trial of a next-generation obesity treatment. 
Via The Motley Fool
News headline image
Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition
Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy ↗
FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps within 15 days. 
Via Benzinga
News headline image
Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over? ↗
Novo Nordisk has been in a downtrend for more than a year. But a reversal may be underway, and a rally may follow. 
Via Benzinga
News headline image
Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment ↗
Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients. 
Via Benzinga
News headline image
3 Undervalued Healthcare Stocks to Buy Now While They're Cheap ↗
In an otherwise hot stock market, healthcare stocks are underperforming. 
Via The Motley Fool
News headline image
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.